Allogene Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Allogene Therapeutics, Inc. (ALLO) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-12
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$146.00K, a 167.91% decline year-over-year.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $146.00K.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$108.00K.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $107.00K, a 67.19% increase from fiscal 2024.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $64.00K.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Allogene Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $678.00K, a 60.70% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 1 month | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | -$108.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $146.00K 10-Q · filed 2026-05-13 | $146.00K derived: sum of 2 quarters · filed 2026-05-13 | $38.00K derived: sum of 3 quarters · filed 2026-05-13 | $253.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$108.00K derived: sum of 2 quarters · filed 2026-03-12 | $107.00K derived: sum of 3 quarters · filed 2026-08-12 | $107.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $107.00K derived: sum of 2 quarters · filed 2026-08-12 | $107.00K 10-Q · filed 2025-11-06 | $171.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $215.00K 10-Q · filed 2026-08-12 | $279.00K derived: sum of 3 quarters · filed 2026-08-12 | $279.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $64.00K derived: sum of 2 quarters · filed 2026-05-13 | $64.00K derived: sum of 3 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $64.00K derived: sum of 2 quarters · filed 2026-03-12 | $64.00K 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | $678.00K 10-K/A · filed 2024-03-14 | ||||
| 2022-06-30 | -$683.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $42.00K 10-Q · filed 2022-08-09 | $655.00K derived: sum of 3 quarters · filed 2024-03-14 | $61.00K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $725.00K 10-Q · filed 2022-05-04 | $1.34M derived: sum of 2 quarters · filed 2024-03-14 | $744.00K derived: sum of 3 quarters · filed 2024-03-14 | -$5.85M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $613.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $19.00K derived: sum of 2 quarters · filed 2024-03-14 | -$6.57M derived: sum of 3 quarters · filed 2024-03-14 | $1.73M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | -$594.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$7.19M derived: sum of 2 quarters · filed 2022-08-09 | $1.11M 10-Q · filed 2021-11-04 | $1.77M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | -$6.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.71M 10-Q · filed 2022-08-09 | $2.36M derived: sum of 3 quarters · filed 2024-03-14 | $1.98M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $8.30M 10-Q · filed 2022-05-04 | $8.96M derived: sum of 2 quarters · filed 2024-03-14 | $8.57M derived: sum of 3 quarters · filed 2024-03-14 | $12.66M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $658.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $269.00K derived: sum of 2 quarters · filed 2024-03-14 | $4.36M derived: sum of 3 quarters · filed 2024-03-14 | $8.57M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | -$389.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.70M derived: sum of 2 quarters · filed 2021-11-04 | $7.91M 10-Q · filed 2021-11-04 | $6.01M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $4.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $8.30M 10-Q · filed 2021-08-04 | $6.39M derived: sum of 3 quarters · filed 2022-02-23 | -$701.00K derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $4.21M 10-Q · filed 2021-05-05 | $2.31M derived: sum of 2 quarters · filed 2022-02-23 | -$4.79M derived: sum of 3 quarters · filed 2022-02-23 | $3.74M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$9.00M derived: sum of 2 quarters · filed 2022-02-23 | -$466.00K derived: sum of 3 quarters · filed 2022-02-23 | $4.67M 10-K · filed 2022-02-23 | |
| 2019-09-30 | -$7.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $1.44M derived: sum of 2 quarters · filed 2020-11-04 | $6.57M 10-Q · filed 2020-11-04 | $9.55M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $8.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $13.67M 10-Q · filed 2020-08-05 | $16.64M derived: sum of 3 quarters · filed 2021-02-25 | $16.79M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $5.13M 10-Q · filed 2020-05-06 | $8.11M derived: sum of 2 quarters · filed 2021-02-25 | $8.26M derived: sum of 3 quarters · filed 2021-02-25 | $8.32M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.12M derived: sum of 2 quarters · filed 2021-02-25 | $3.18M derived: sum of 3 quarters · filed 2021-02-25 | $3.18M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $204.00K derived: sum of 2 quarters · filed 2019-11-05 | $204.00K 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $60.00K 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |